BioMarin Pharmaceutical Inc
BMRN55.140USD
+0.770+1.42%
Close 09/18, 16:00（ET）Quotes delayed by 15 min
10.59BMarket Cap
16.11P/E TTM
More Details of BioMarin Pharmaceutical Inc Company
BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.
Company Info
Ticker SymbolBMRN
Company nameBioMarin Pharmaceutical Inc
IPO dateJul 23, 1999
CEOMr. Alexander Hardy
Number of employees3040
Security typeOrdinary Share
Fiscal year-endJul 23
Address770 Lindaro Street
CitySAN RAFAEL
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code94901
Phone14155066700
Websitehttps://www.biomarin.com/
Ticker SymbolBMRN
IPO dateJul 23, 1999
CEOMr. Alexander Hardy
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Richard A. (Randy) Meier
Mr. Richard A. (Randy) Meier
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
120.34K
+5.85%
Mr. Alexander Hardy
Mr. Alexander Hardy
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
62.99K
-53.04%
Dr. Gregory R Friberg, M.D.
Dr. Gregory R Friberg, M.D.
Executive Vice President, Chief Research & Development Officer
Executive Vice President, Chief Research & Development Officer
46.81K
+61.08%
Mr. Robert J. (Bob) Hombach, CPA
Mr. Robert J. (Bob) Hombach, CPA
Independent Director
Independent Director
37.15K
+21.80%
Ms. Cristin Hubbard
Ms. Cristin Hubbard
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
30.55K
-7.36%
Dr. Maykin Ho, Ph.D.
Dr. Maykin Ho, Ph.D.
Independent Director
Independent Director
23.29K
+39.97%
Dr. Athena M. Countouriotis, M.D.
Dr. Athena M. Countouriotis, M.D.
Independent Director
Independent Director
8.83K
+305.05%
Ms. Barbara W. Bodem
Ms. Barbara W. Bodem
Independent Director
Independent Director
8.83K
+305.05%
Ms. Elizabeth Mckey Anderson
Ms. Elizabeth Mckey Anderson
Independent Director
Independent Director
--
--
Mr. Timothy Walbert
Mr. Timothy Walbert
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Richard A. (Randy) Meier
Mr. Richard A. (Randy) Meier
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
120.34K
+5.85%
Mr. Alexander Hardy
Mr. Alexander Hardy
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
62.99K
-53.04%
Dr. Gregory R Friberg, M.D.
Dr. Gregory R Friberg, M.D.
Executive Vice President, Chief Research & Development Officer
Executive Vice President, Chief Research & Development Officer
46.81K
+61.08%
Mr. Robert J. (Bob) Hombach, CPA
Mr. Robert J. (Bob) Hombach, CPA
Independent Director
Independent Director
37.15K
+21.80%
Ms. Cristin Hubbard
Ms. Cristin Hubbard
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
30.55K
-7.36%
Dr. Maykin Ho, Ph.D.
Dr. Maykin Ho, Ph.D.
Independent Director
Independent Director
23.29K
+39.97%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Voxzogo
213.75M
29.10%
Vimizim
188.35M
25.64%
Naglazyme
114.29M
15.56%
Palynziq
93.27M
12.70%
Aldurazyme
48.98M
6.67%
Other
76.01M
10.35%
By RegionUSD
Name
Revenue
Proportion
United States
241.69M
32.90%
Europe
229.58M
31.25%
Rest of the world
126.11M
17.17%
Latin America
88.28M
12.02%
ALDURAZYME net product revenues marked by Sanofi
48.98M
6.67%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Voxzogo
213.75M
29.10%
Vimizim
188.35M
25.64%
Naglazyme
114.29M
15.56%
Palynziq
93.27M
12.70%
Aldurazyme
48.98M
6.67%
Other
76.01M
10.35%
Shareholding Stats
Updated: Sat, Aug 16
Updated: Sat, Aug 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.85%
BlackRock Institutional Trust Company, N.A.
9.39%
PRIMECAP Management Company
8.21%
Dodge & Cox
7.87%
Viking Global Investors LP
6.40%
Other
58.27%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.85%
BlackRock Institutional Trust Company, N.A.
9.39%
PRIMECAP Management Company
8.21%
Dodge & Cox
7.87%
Viking Global Investors LP
6.40%
Other
58.27%
Shareholder Types
Shareholders
Proportion
Investment Advisor
43.86%
Investment Advisor/Hedge Fund
39.63%
Hedge Fund
7.66%
Pension Fund
3.19%
Research Firm
1.70%
Sovereign Wealth Fund
1.23%
Bank and Trust
1.17%
Individual Investor
0.75%
Venture Capital
0.34%
Other
0.47%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
1333
195.10M
101.61%
-16.01M
2025Q1
1355
191.53M
99.87%
-20.72M
2024Q4
1336
190.53M
99.88%
-17.50M
2024Q3
1308
188.26M
98.81%
-22.17M
2024Q2
1293
192.58M
101.18%
-14.21M
2024Q1
1278
194.24M
102.38%
-11.23M
2023Q4
1294
193.16M
102.42%
-3.22M
2023Q3
1275
188.66M
100.18%
-4.68M
2023Q2
1283
185.80M
98.76%
-8.08M
2023Q1
1274
186.38M
99.36%
-9.64M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
18.92M
9.87%
-369.57K
-1.92%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
18.12M
9.45%
-16.94K
-0.09%
Mar 31, 2025
PRIMECAP Management Company
17.77M
9.27%
-415.89K
-2.29%
Mar 31, 2025
Dodge & Cox
14.96M
7.8%
+209.00K
+1.42%
Mar 31, 2025
Viking Global Investors LP
10.80M
5.63%
+289.51K
+2.75%
Mar 31, 2025
State Street Global Advisors (US)
8.46M
4.41%
-649.18K
-7.12%
Mar 31, 2025
AQR Capital Management, LLC
2.93M
1.53%
+1.64M
+127.94%
Mar 31, 2025
Geode Capital Management, L.L.C.
3.43M
1.79%
+142.47K
+4.33%
Mar 31, 2025
Norges Bank Investment Management (NBIM)
3.57M
1.86%
-49.67K
-1.37%
Dec 31, 2024
View more
Related ETFs
Updated: Sat, Sep 6
Updated: Sat, Sep 6
Name
Proportion
First Trust Mid Cap Growth AlphaDEX Fund
0%
First Trust Mid Cap Core Alphadex Fund
0%
Goldman Sachs Equal Weight US Large Cap Equity ETF
0%
AGF US Market Neutral Anti-Beta Fund
0%
iShares S&P Mid-Cap 400 Growth ETF
0%
iShares Russell 1000 Growth ETF
0%
First Trust Lunt US Factor Rotation ETF
0%
SPDR S&P 400 Mid Cap Growth ETF
0%
QRAFT AI-Enhanced US Large Cap ETF
0%
WisdomTree US LargeCap Fund
0%
View more
First Trust Mid Cap Growth AlphaDEX Fund
Proportion0%
First Trust Mid Cap Core Alphadex Fund
Proportion0%
Goldman Sachs Equal Weight US Large Cap Equity ETF
Proportion0%
AGF US Market Neutral Anti-Beta Fund
Proportion0%
iShares S&P Mid-Cap 400 Growth ETF
Proportion0%
iShares Russell 1000 Growth ETF
Proportion0%
First Trust Lunt US Factor Rotation ETF
Proportion0%
SPDR S&P 400 Mid Cap Growth ETF
Proportion0%
QRAFT AI-Enhanced US Large Cap ETF
Proportion0%
WisdomTree US LargeCap Fund
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
